Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
Authors:
- Frank BertholdFrank Berthold
- Angela ErnstAEAngela Ernst
- Sandra AckermannSASandra Ackermann
- Christoph BartenhagenCBChristoph Bartenhagen
- Holger ChristiansenHCHolger Christiansen
- Barbara HeroBHBarbara Hero
- Carolina RosswogCRCarolina Rosswog
- Dietrich von SchweinitzDSDietrich von Schweinitz
- Thomas KlingebielTKThomas Klingebiel
- Irene SchmidISIrene Schmid
- Thorsten SimonTSThorsten Simon
- Matthias FischerMFMatthias Fischer
Open Access
Abstract
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-risk group solely by the presence of MYCN oncogene amplification (MNA). Methods: Clinical characteristics, genomic information, and outcome of 190 patients solely assigned to high-risk neuroblastoma by MNA were analyzed and compared to 205 patients with stage 4 neuroblastoma aged ≥18 months with MNA (control group). Results: Event-free survival (EFS) and overall survival (OS) at 10 years were 47% (95%-CI 39–54%) and 56% (95%-CI 49–63%), respectively, which was significantly better than EFS and OS of the control group (EFS 25%, 95%-CI 18–31%, p < 0.001; OS 32% 95%-CI 25–39%, p < 0.001). The presence of RAS-/p53-pathway gene alterations was associated with impaired 10-year EFS and OS (19% vs. 55%, and 19% vs. 67%, respectively; both p < 0.001). In time-dependent multivariable analyses, alterations of RAS-/p53-pathway genes and the extent of the best primary tumor resection were the only independent prognostic variables for OS (p < 0.001 and p = 0.011, respectively). Conclusions: Neuroblastoma patients attributed to high risk solely by MYCN amplification have generally a more favorable outcome. Mutations of genes of the RAS and/or p53 pathways and incomplete resection are the main risk factors predicting poor outcome.Keywords
Funding Information
- Deutsche Krebshilfe (Grant 70-2290-Be; Grant 70107712)
- Deutsche Kinderkrebshilfe (Grants 96.06 and 99.03)
- Else Kröner-Fresenius-Stiftung (2016-Kolleg-19)
This publication has 33 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at DiagnosisJournal of Clinical Oncology, 2013
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeBritish Journal of Cancer, 2009
- Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group DatabaseJournal of Clinical Oncology, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Outcome of high‐risk stage 3 neuroblastoma with myeloablative therapy and 13‐cis‐retinoic acid: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008
- Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell PloidyJournal of Clinical Oncology, 2005
- The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 diseaseCancer, 2005
- Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines*†Medical and Pediatric Oncology, 2001